HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema

Files in This Item:
AO88-3_377-380.pdf230.72 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/45372

Title: Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema
Authors: Saito, Wataru Browse this author →KAKEN DB
Kase, Satoru Browse this author →KAKEN DB
Ohgami, Kazuhiro Browse this author →KAKEN DB
Mori, Shohei Browse this author
Ohno, Shigeaki Browse this author →KAKEN DB
Keywords: bevacizumab
exudative retinal detachment
macular oedema
retinal hamartomas
tuberous sclerosis
vascular endothelial growth factor
Issue Date: May-2010
Publisher: Blackwell Publishing
Journal Title: Acta Ophthalmologica
Volume: 88
Issue: 3
Start Page: 377
End Page: 380
Publisher DOI: 10.1111/j.1755-3768.2008.01331.x
PMID: 18778334
Abstract: Purpose: To describe two patients with macular oedema secondary to tuberous sclerosis complex (TSC), who were treated with intravitreal bevacizumab injection. Methods: Interventional case reports. Bevacizumab 1.25 mg was injected into the vitreous of two patients with TSC-associated macular oedema / exudative retinal detachment. VEGF concentration in the vitreous fluid was measured by ELISA in one of these patients. Results: Case 1. 22-year-old woman with TSC was diagnosed as having multiple retinal hamartomas in both eyes. Eleven years later, the patient developed macular oedema with epiretinal membrane formation in the right eye. The patient underwent pars plana vitrectomy with retinal photocoagulation for retinal tumours. VEGF concentration in the vitreous fluid was high compared to that in patients without retinal vascular diseases. Recurrent macular oedema was resolved by intravitreal injection of bevacizumab. Case 2. 32-year-old woman with TSC-associated retinal hamartoma, temporally showing macular exudative retinal detachment, developed the neovascularization originated from the tumour. By intravitreal bevacizumab injection, the tumour size markedly reduced with regression of neovascularization. Conclusions: These results suggest that VEGF derived from retinal hamartomas causes macular oedema associated with TSC. Intravitreal injections of bevacizumab may be a useful therapeutic option for macular oedema secondary to TSC.
Rights: The definitive version is available at www.blackwell-synergy.com
Type: article (author version)
URI: http://hdl.handle.net/2115/45372
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 齋藤 航

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University